Over 1,000 Syrian settlements join reconciliation process - Russian defense ministryWorld December 06, 3:27
Italian president asks Renzi to delay resignation until budget passedWorld December 06, 3:24
Senior Russian MP blames deadly Aleppo hospital shelling on oppositionWorld December 06, 3:20
Kiev plans to discuss Russian gas purchases on December 9 — NaftogazBusiness & Economy December 06, 0:38
Russia, China veto UN Security Council resolution on Aleppo ceasefireWorld December 05, 23:10
Putin tells about his dream, alcohol tests and advises not to neglect personal lifeSociety & Culture December 05, 23:05
UN Security Council should vote on Aleppo after US-Russian talks — envoyWorld December 05, 22:21
Putin says confident in development of Russian helicopter industryMilitary & Defense December 05, 21:15
Russian diplomat hopes Aleppo’s liberation will pave way for political dialogueRussian Politics & Diplomacy December 05, 21:13
NOVOSIBIRSK, November 14 (Itar-Tass) - Scientists at Russia's SibEnzyme enterprise in the Siberian city of Novosibirsk have developed a brand new method to diagnose oncological diseases at very early stages, the company’s chief executive, Yevgeny Dubinin, told Itar-Tass at the international forum for technological development Technoprom.
The new method allows to detect cancer cells even if the sample under scrutiny (blood, phlegm, urine or smear) contains only few DNA molecules with abnormally methylated (abnormally working, ‘silent’ genes), according to Dubinin.
The company’s enzyme, whose patented technology detects methylated genes, is used as a tumor marker. Analysis is simple and reliable - carried out on standard equipment, in one vial and in three stages, it takes only about four hours.
“There is almost no early cancer diagnostic in Russia, while treating the disease when it is detected at the third and fourth stages yields little effect,” Dubinin said.
The new method will be indispensable for oncological centres, diagnostic laboratories, and other medical institutions, the director added. The estimated market volume is about 5.5 million examinations and 1.8 million for rare types of cancer.